Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.66%
$70.71
0% positive prob.
5-Day Prediction
-2.77%
$69.91
0% positive prob.
20-Day Prediction
-2.62%
$70.01
0% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q2 2026 | SELL | -1.66% | -2.77% | -2.62% | 100.0% | Pending |
| Q2 2026 | SELL | -1.66% | -2.77% | -2.62% | 100.0% | +12.82% |
| Q1 2026 | BUY | +2.74% | +3.36% | +10.22% | 100.0% | +3.51% |
| Q4 2025 | SELL | -1.81% | -2.62% | -2.18% | 100.0% | -4.10% |
SEC 8-K filings with transcript text
Jul 29, 2026 · 100% conf.
1D
-1.66%
$60.96
Act: -2.27%
5D
-2.77%
$60.28
Act: +12.82%
20D
-2.62%
$60.36
gehc-20260729
0001932393false00019323932026-07-292026-07-29
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 29, 2026
(Exact name of registrant as specified in its charter)
Delaware001-4152888-2515116
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
500 W. Monroe Street, Chicago, IL 60661
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code) (833) 735-1139
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.01 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition.
On July 29, 2026, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its second quarter 2026 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K.
The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription
99
Press release of GE HealthCare Technologies Inc., dated July 29, 2026.
104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GE HealthCare Technologies Inc.
(Registrant)
Date: July 29, 2026 /s/ George A. Newcomb
George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
Jul 23, 2026 · 100% conf.
1D
-1.66%
$60.96
Act: -2.27%
5D
-2.77%
$60.28
Act: +12.82%
20D
-2.62%
$60.36
2 form8-kex99_72126.htm
Document
Exhibit 99
GE HealthCare announces CFO transition; reports preliminary second quarter 2026 financial results and reaffirms guidance reflecting business momentum
•James (Jay) Saccaro to step down as Chief Financial Officer (CFO) of GE HealthCare
•Preliminary second quarter results reflect business momentum: On a year-over-year basis, Revenue growth of 5.7% and Organic revenue growth* of 3.5%; Adjusted earnings per share (EPS)* performance ahead of prior expectation
•Reaffirms full-year 2026 guidance
CHICAGO — July 23, 2026 — GE HealthCare (Nasdaq: GEHC) today announced that Jay Saccaro will step down as Vice President and Chief Financial Officer for an expanded role outside of the medical technology industry. The Company has appointed George Newcomb, currently Controller and Chief Accounting Officer, as interim Chief Financial Officer. Mr. Saccaro will remain with the Company through August 14, 2026, and work together with Mr. Newcomb to ensure a smooth transition. GE HealthCare has commenced a search for a permanent successor.
GE HealthCare President and Chief Executive Officer Peter Arduini said, “On behalf of the Board of Directors and executive team, I would like to thank Jay for his contributions over the past three years. He has played a key role in driving financial discipline and strategic investments aligned to our capital allocation strategy. We wish him success in his next endeavor.”
Mr. Saccaro said, “It has been a privilege to serve as GE HealthCare's CFO and lead its outstanding finance organization. I want to thank Peter, the Board, and my colleagues for their partnership over the past three years and I wish the company continued success.”
George Newcomb is an accomplished financial professional with more than 38 years’ experience in Finance leadership positions at various companies. Mr. Newcomb has served as the Controller of GE HealthCare since February 2016 and was additionally named as Chief Accounting Officer as a part of the spin off from General Electric Company (GE) in 2023. From 1996 to February 2016, he held a variety of finance leadership roles at GE Capital, including as Capital Planning and Finance Readiness Leader of GE Capital Americas (“GECA”), Controller of GECA, and CFO roles at Bank BPH, GE Capital Equipment Finance, and GE Capital Healthcare Financial Services. Prior to GE Capital, he was a Senior Tax Manager at Arthur Andersen. He has a bachelor’s degree in accounting from the Pennsylvania State University and an M.B.A. from New York University’s Stern School of Business.
Today, the Company is also providing certain preliminary, unaudited results for the second quarter ending June 30, 2026. GE HealthCare expects to report year-over-year Revenue growth of 5.7% and Organic revenue growth* of 3.5%. The Company expects to report year-over-year growth in diluted EPS and Adjusted EPS*, above its prior expectation. For the full-year 2026, the company reaffirms guidance provided on April 29, 2026. The Company will provide additional details when it reports complete second quarter results on July 29, 2026.
* Non-GAAP financial measure.
“We are pleased with the momentum in our business, reflecting strong orders, healthy end market demand, traction with new products, and continued commercial execution,” said Mr. Arduini.
This release contains financial results that are preliminary, unaudited, and subject to change in connection with the completion of the Company's quarterly financial closing process. These preliminary results are not a comprehensive statement of the Company's financial results for the quarter ended June 30, 2026, and should not be viewed as a substitute for financial statements prepared in accordance with U.S. GAAP. Undue reliance should not be placed on these preliminary estimates.
GE HealthCare will discuss its complete second quarter results during its earnings call on July 29, 2026, at 8:30 am ET. The webcast and accompanying presentation can be accessed at https://investor.gehealthcare.com/news-events/events.
Non-GAAP financial measures
The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.
The Company reports Organic revenue growth rate to provide management and investors with additional understanding and visibility into the underlying revenue trends of the Company’s established, ongoing operations, as well as provide insights i
Apr 29, 2026 · 100% conf.
1D
+2.74%
$61.27
Act: +2.01%
5D
+3.36%
$61.64
Act: +3.51%
20D
+10.22%
$65.73
Act: +5.40%
gehc-20260429
0001932393false00019323932026-04-292026-04-29
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 29, 2026
(Exact name of registrant as specified in its charter)
Delaware001-4152888-2515116
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
500 W. Monroe Street, Chicago, IL 60661
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code) (833) 735-1139
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $0.01 per share
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐
Item 2.02 Results of Operations and Financial Condition.
On April 29, 2026, GE HealthCare Technologies Inc. (“GE HealthCare”) issued a press release announcing its first quarter 2026 financial results. A copy of this press release is furnished as Exhibit 99 to this Current Report on Form 8-K.
The information furnished pursuant to Item 2.02, including Exhibit 99, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of GE HealthCare under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
ExhibitDescription
99
Press release of GE HealthCare Technologies Inc., dated April 29, 2026.
104The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GE HealthCare Technologies Inc.
(Registrant)
Date: April 29, 2026 /s/ George A. Newcomb
George A. Newcomb, Controller & Chief Accounting Officer (authorized signatory)
This page provides GE HealthCare Technologies Inc. (GEHC) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on GEHC's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.